Form 483

Novartis Innovative Technologies Inc. Form 483, 2024-01-26

FDA issued a Form 483 to Novartis Innovative Technologies Inc. on 2024-01-26 with 2 public-safe observations.

483· Form 483 issuedBiologics2 observations

Novartis Innovative Technologies Inc. · Durham, United States · Issued January 26, 2024

Overview

  • 2 public-safe observations are available for this inspection.
  • 2 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

26 Jan 2024
21 CFR 211.192

Extent of discrepancy, failure investigations

Cited by Unnee Ranjan, Thai D Truong

26 Jan 2024
21 CFR 600.14(c)

When to report

Cited by Unnee Ranjan, Thai D Truong

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 600.14(c)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 2 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere